Phosphoribosyl triphosphate

AMP, ADP, and ATP = adenosine mono-, di-, and triphosphate IMP = inosine 5 -monophosphate AICAR = 5 -phosphoribosyl-5-amino-4-imida2olecarboxamide DAP = diaminopimelic acid PRPP = phosphoribosyl pyrophosphate a — KGA = a-ketoglutaric acid Orn = ornithine Cit = citnilline represents the one carbon unit lost to tetrahydrofolate as serine is converted to glycine. 

Fig. 13.1 Pathways of thiopurine metabolism. The positions of two polymorphically expressed enzymes, TPMT (thiopurine methyl transferase) and ITPA (inosine triphosphate pyrophosphatase), are shown. HGPRT, hypoxanthine guanine phosphoribosyl transferase 6-TIDP, 6-thioi-nosine diphosphate 6-TIMP, 6-thioinosine monophosphate 6-TITP, 6-thio inosine trinophosphate...

The first step of this sequence, which is not unique to de novo purine nucleotide biosynthesis, is the synthesis of 5-phosphoribosylpyrophosphate (PRPP) from ribose-5-phosphate and adenosine triphosphate. Phosphoribosyl-pyrophosphate synthetase, the enzyme that catalyses this reaction [278], is under feedback control by adenosine triphosphate [279]. Cordycepin interferes with thede novo pathway [229, 280, 281), and cordycepin triphosphate inhibits the synthesis of PRPP in extracts from Ehrlich ascites tumour cells [282]. Formycin [283], probably as the triphosphate, 9-0-D-xylofuranosyladenine [157] triphosphate, and decoyinine (LXXlll) [284-286] (p. 89) also inhibit the synthesis of PRPP in tumour cells, and this is held to be the blockade most important to their cytotoxic action. It has been suggested but not established that tubercidin (triphosphate) may also be an inhibitor of this reaction [193]. 

Recently, the formation of a covalent glycosyl-enzyme intermediate was also shown by Bell and Koshland (17) in another reaction. Evidence was presented that the mechanism of the enzyme, phosphoribosyl-adeno-sine triphosphate pyrophosphate phosphoribosyl transferase, proceeds through a covalent phosphoribosyl-enzyme intermediate. The intermediate has been demonstrated after incubating the enzyme with 14C-5-phosphoribosyl-l-pyrophosphate (PRPP) under native and denaturing conditions. The intermediate also forms from the reverse direction as shown when the enzyme is mixed with its product N- (5-phosphoribosyl-adenosine triphosphate (PR-ATP). These data give evidence for a covalent enzyme-substrate intermediate. The enzyme which catalyzes the overall reaction proceeds as follows ... 

Didanosine is a synthetic purine nucleoside analog that inhibits the activity of reverse transcriptase in HIV-1, HIV-2, other retroviruses and zidovudine-resistant strains. A nucleobase carrier helps transport it into the cell where it needs to be phosphorylated by 5 -nucleoiidase and inosine 5 -monophosphate phosphotransferase to didanosine S -monophosphate. Adenylosuccinate synthetase and adenylosuccinate lyase then convert didanosine 5 -monophosphate to dideoxyadenosine S -monophosphate, followed by its conversion to diphosphate by adenylate kinase and phosphoribosyl pyrophosphate synthetase, which is then phosphorylated by creatine kinase and phosphoribosyl pyrophosphate synthetase to dideoxyadenosine S -triphosphate, the active reverse transcriptase inhibitor. Dideoxyadenosine triphosphate inhibits the activity of HIV reverse transcriptase by competing with the natural substrate, deoxyadenosine triphosphate, and its incorporation into viral DNA causes termination of viral DNA chain elongation. It is 10-100-fold less potent than zidovudine in its antiviral activity, but is more active than zidovudine in nondividing and quiescent cells. At clinically relevant doses, it is not toxic to hematopoietic precursor cells or lymphocytes, and the resistance to the drug results from site-directed mutagenesis at codons 65 and 74 of viral reverse transcriptase. 

Fig. 2 Metabolism of 6-mercaptopurine (6-MP) via xanthine oxidase (XO) to the inactive metabolite 6-thiouric acid (6-TU), thiopurine S-methyltransferase (TPMT) to the inactive metabolite 6-methylmercaptopurine (6-MMP), and hypoxanthine guanine phosphoribosyl transferase (HPRT) to 6-thioinosine monophosphate (6-TIMP) which is then further metabolized to thioguanine nucleotides (6-TGN), 6-methylmercaptopurine ribonucleotides (6-MMPR) or 6-thio-inosine triphosphate (6-thio-ITP), these all being active metabolites...

Fluorouracil (5-FU) requires enzymatic conversion to the nucleotide (ribosylation and phosphorylation) in order to exert its cytotoxic activity. Several routes are available for the formation of floxuridine monophosphate (FUMP). 5-FU may be converted to fluorouridine by uridine phos-phorylase and then to FUMP by uridine kinase, or it may react directly with 5-phosphoribosyl-l-pyrophosphate (PRPP), in a reaction catalyzed by orotate phosphoribosyl transferase, to form FUMP. Many metabolic pathways are available to FUMP. As the triphosphate FUTP, it may be incorporated into RNA. An alternative reaction sequence... 

Histidine 44 Cyclase Phosphoribosyl-adenosine triphosphate-pyro-phosphorylase ... 

Susceptible fungi deaminate flucytosine to 5-fluorouracil, a potent antimetabolite (Figure 48—2). Fluorouracil is metabolized to 5-fluorouracil-ribose monophosphate (5-FUMP) by the enzyme uracil phosphoribosyl transferase (UPRTase). 5-FUMP then is either incorporated into RNA (via synthesis of 5-fluorouridine triphosphate) or metabolized to 5-fluoro-2 -deoxyuridine-5 -monophosphate (5-FdUMP), a potent inhibitor of thymidylate synthetase that thus inhibits DNA synthesis. The selective action of flucytosine is due to the relatively low level of cytosine deaminase in mammalian cells, which prevents metabolism to fluorouracil. 

FIGURE 50-3 Intracellular activation of nucleoside analog reverse transcriptase inhibitors. Drugs and phosphory-lated anabolites are abbreviated the enzymes responsible for each conversion are spelled out. The active antiretroviral anabolite for each drug is shown in the blue box. Key ZDV, zidovudine d4T, stavudine ddC, dideoxycytidine FTC, emtricitabine 3TC, lamivudine ABC, abacavir ddl, didanosine DF, disoproxil fumarate MP, monophosphate DP, diphosphate TP, triphosphate AMP, adenosine monophosphate CMP, cytosine monophosphate dCMP, deoxycytosine monophosphate IMP, inosine 5 -monophosphate PRPP, phosphoribosyl pyrophosphate NDR, nucleoside diphosphate. 

FIGURE 51-5 Activation pathways for 5 fluorouracil (5-FU) and 5-floxuridine (FUR). FUDP, floxuridine diphosphate FUMP, floxuridine monophosphate FUTP, floxuridine triphosphate FUdR, fluorodeoxyuridine FdUDP fluorodeoxyuridine diphosphate FdUMP fluorodeoxyuridine monophosphate FdUTP fluorodeoxyuridine triphosphate PRPP 5-phosphoribosyl-1 -pyrophosphate. 

Pyrimidine bases are first synthesized as the free base and then converted to a nucleotide. Aspartate and carbamoyl phosphate form all components of the pyrimidine ring. Ribose 5-phosphate, which is converted to phosphoribosyl pyrophosphate (PRPP), is required to donate the sugar phosphate to form a nucleotide. The first pyrimidine nucleotide produced is orotate monophosphate (OMP). The OMP is converted to uridine monophosphate (UMP), which will become the precursor for both cytidine triphosphate (CTP) and deoxythymidine monophosphate (dTMP) production. 

The committed step of purine synthesis is the formation of 5-phosphoribosyl 1-amine by glutamine phosphoribosyl amidotransferase. This enzyme is strongly inhibited by GMP and AMP (the end products of the purine biosynthetic pathway). The enzyme is also inhibited by the corresponding nucleoside di- and triphosphates, but under cellular conditions, these compounds probably do not play a central role in regulation. The active enzyme is a monomer of 133,000 daltons but is converted to an inactive dimer (270,000 daltons) by binding of the end products. 

M15. Murray, A. W., and Wong, P. C. L., Stimulation of adenine Phosphoribosyl-transferase by adenosine triphosphate and other nucleoside triphosphates. Biochem. J. 104, 669 (1967). 

The first reaction in His biosynthesis involves the transfer of N-1 and C-2 of the adenine moiety of ATP to the ribose phosphate unit of 5-phosphoribosyl-1 -pyrophosp hate (PRPP) (Figure 5.82). The key intermediate PRPP is condensed by the N -5 -phosphoribosyl-adenosine triphosphate (PRATP) transferase (encoded by gene... 

The synthesis of nucleotide triphosphates required for polynucleotide chain building is a complex process which will not be considered in full detail here. The biosynthetic routes for purine and pyrimidine nucleosides are somewhat different and commence with 5 phosphoribosyl-l-pyrophos-phate and carbamyl phosphate, respectively. These two materials undergo successive enzyme-catalysed reactions, linking at times with compounds encountered in other biochemical cycles, and utilising ATP in several stages. Polynucleotides can be synthesised by purely chemical means in the laboratory (Chapter 10.4). 

Pyrimidine biosynthesis commences with a reaction between carbamyl phosphate and aspartic acid to give carbamyl aspartic acid which then nndergoes ring closure and oxidation to orotic acid. A reaction then occurs between orotic acid and 5-phosphoribosyl pyrophosphate to give orotidine-5-phosphate which on decarboxylation yields uridine-5-phosphate (UMP). By means of two successive reactions with ATP, UMP can then be converted into UTP and this by reaction with ammonia can give rise to cytidine triphosphate, CTP (11.126). 

Figure 1 The metabolism of azathioprine and mercaptopurine Key AO, aldehyde ojddase GMPS, guanine monophosphate synthetase HPRT, hypoxanthine phosphoribosyl transferase IMPDH, inosine monophosphate dehydrogenase ITPA, inosine triphosphate pyrophosphohydrolase TPMT, thiopurine methyltransfer-ase XO/XDH, xanthine oxidase/dehydrogenase.

The substrate specificity of adenylosuccinate synthetase is strict inosi-nate cannot be replaced by hypoxanthine, inosine, or phosphoribosyl aminoimidazole carboxamide L-aspartate cannot be replaced by ammonia or other d- or L-amino acids and other nucleoside mono-, di-, and triphosphates cannot replace GTP. Divalent cations are required. Bacterial, plant, and animal enzymes have similar specificities and general properties, although Michaelis constants differ somewhat. These are approximately 10 to 10 Af for GTP and aspartate, and 3 X Iff" M for ino-sinate. 

Aspartate carbamyltransferase 2 dihydroorotase 3 orotate reductase 4 orotate phosphoribosyl-transferase 5 orotidine-5 -phosphate decarboxylase 6 cytidylate kinase, nucleotide diphosphate kinase 7 cytidine triphosphate synthetase 8 nucleoside monophosphate kinase, ribonucleoside diphosphate reductase, phosphatase 9 thymidylate synthase... 

---